

<i>Proteus</i> spp. (n=16,908 from 68 Hospitals)			
	Susceptibility (Range)	Number of Isolates	Number of Hospitals
Ampicillin-Sulbactam	-	-	-
Piperacillin-Tazobactam	97.5% (31-100%)	15,836	63
Ceftriaxone	90.4% (67-99%)	15,682	61
Ceftazidime	91.6% (63-100%)	13,067	49
Cefepime	91.7% (61-100%)	13,832	52
Ertapenem	98.9% (88-100%)	9,018	32
Imipenem	70.8% (11%-100%)	3,561	16
Meropenem	98.5% (63-100%)	9,903	32
Amikacin	98.7% (87-100%)	13,470	53
Gentamicin	82.9% (61-93%)	16,554	66
Tobramycin	84.1% (67-100%)	10,176	49
Ciprofloxacin/Levofloxacin	67.8% (27-97%)	16,738	67
TMP-SMX	67.6% (35-100%)	16,491	66

Comments from LA County Healthcare-Associated Infection and Antibiotic Resistance Committee:

Proteus, Providencia, and Morganella are intrinsically less susceptible to imipenem than to meropenem. Imipenem should not be used to classify Proteus / Providencia / Morganella isolates as CRE.

Clinicians should not use results of imipenem testing to infer activity of meropenem for any species.